<DOC>
	<DOCNO>NCT01589419</DOCNO>
	<brief_summary>An open-label , Phase 1b , dose escalation study evaluate safety tolerability PARP inhibitor Veliparib combination capecitabine radiation subject locally advanced rectal cancer ( LARC ) .</brief_summary>
	<brief_title>A Clinical Study Conducted Multiple Centers Evaluating Escalating Doses Veliparib Combination With Capecitabine Radiation Patients With Locally Advanced Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Subject must â‰¥ 18 year age All subject must newly diagnose , histologically proven adenocarcinoma rectum All subject must abdominal/pelvis compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) confirm evidence distant metastasis Distal border tumor &lt; 12 cm anal verge Subjects must Eastern Cooperative Oncology Group ( ECOG ) Performance Score 0 2 No prior treatment LARC however prior treatment cancer acceptable long consider curative Subject unsuitable candidate TME surgery Subject receive anticancer therapy Subject receive prior radiation therapy Subject major surgery within 28 day prior first dose study drug History gastric surgery , vagotomy , bowel resection surgical procedure might interfere gastrointestinal motility , pH absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>DLT</keyword>
	<keyword>radiation</keyword>
	<keyword>veliparib</keyword>
	<keyword>locally advanced rectal cancer</keyword>
	<keyword>ABT-888</keyword>
	<keyword>capecitabine</keyword>
	<keyword>MTD</keyword>
	<keyword>PARP</keyword>
</DOC>